Gabor M. Rubanyi

Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA.

Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey.

Epoch Biosciences, Inc. manufactures and develops molecular tools for genetic analysis. Its technology has numerous applications including the detection of inherited diseases and single nucleotide polymorphisms to identify individuals at risk for disease or adverse drug reactions and gene expression measurement. The company was founded in 1985 and is headquartered in Bothell, WA.

Part of Bayer AG, Schering Berlin, Inc. is a company that manufactures pharmaceuticals and diagnostic substances. The company is based in Whippany, NJ.

Reliant Pharmaceuticals, Inc. sells, markets and develops cardiovascular pharmaceutical products. The company focuses on marketing promotionally sensitive pharmaceutical products to the primary care, cardiovascular and specialist physician markets in the United States. The company is headquartered in Liberty Corner, NJ

EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California.

Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States.

EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA.

ECE Group GmbH & Co. KG engages in the development and construction of commercial and industrial centers and properties. It offers general planning and contracting, architecture, construction management, project development and management, marketing and sales, leasing, refurbishment, center management, and master planning. The company was founded by Werner Otto in 1965 and is headquartered in Hamburg, Germany.

Synchronicity Pharma, Inc. discovers, develops and commercializes novel therapeutics. Its products identify components of the circadian system that can be targeted to treat metabolic and related disorders, such as diabetes, obesity, and cardiovascular diseases. The company was founded by Ross S. Bersot, Joseph S. Takahashi, Masashi Yanagisawas and Ron Evans in 2008 and is headquartered in San Jose, CA.

IIF Management Co LLC (Illumina Ventures) is a venture capital firm founded in 2015 by Nicholas J. Naclerio. The firm is headquartered in Foster City, California.

Bay City Capital GF Xinde International Life Sciences USD Fund LP invests in companies located United States, Canada, Western Europe and China. The Fund targets companies operating in the fields of life sciences. It provides financing for seed, early and later stage capital requirements.

KBP Biosciences engages in conducting biotechnological research to develop therapies for patients. The company was founded by Huang Zhenhua in and is headquartered in Princeton, NJ.

Imidomics, Inc. is an American biotechnology company that focuses on discovering and developing new medicines for immune-mediated inflammatory diseases (IMIDs). The company is based in an undisclosed location. Imidomics has access to the IMID-biobank, which includes real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications. The company utilizes a proprietary digital bioinformatics portal called the Imidomics Precision Discovery Platform to generate novel insights into disease mechanisms and identify potential new drug targets. The company was founded in Barcelona in 2015 by Dr. Sara Marsal and Dr. Richard M. Myers. The CEO of the company is Fred Bernard Craves.